Organization
Novatim Immune Therapeutics (Zhejiang)
2 clinical trials
1 abstract
Clinical trial
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KY-0118 in Subjects With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-28
Clinical trial
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Characterization of KQ-2003 for Patients With Relapsed/Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-03-31
Abstract
Dose escalation of KY-0118, PD-1, and IL-2v due-target fusion protein in patients with advanced renal clear cell carcinoma, urothelial carcinoma, and malignant melanoma.Org: Novatim Immune Therapeutics (Zhejiang), Shanghai, China, Gracell Biotechnologies, Ltd., Fudan University, Shanghai, China,